AstraZeneca's Imfinzi-Chemotherapy Combination Improved Biliary Tract Cancer Survival
25 October 2021 - 5:46PM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said on Monday that results from its TOPAZ-1
Phase 3 trial on its human monoclonal antibody, Imfinzi, showed it
significantly improved overall survival in advanced biliary tract
cancer patients.
The London-listed pharmaceutical company said Imfinzi, in
combination with standard-of-care chemotherapy, showed a
"statistically significant and clinically meaningful" overall
survival when compared with chemotherapy alone.
"We believe the significant survival benefit demonstrated marks
a new era of immunotherapy treatment in this devastating disease,
and it advances our commitment to improving long-term survival for
patients across these cancers where treatment options are limited,"
the company said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
October 25, 2021 02:31 ET (06:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From May 2023 to May 2024